Targeting the complement system for the management of retinal inflammatory and degenerative diseases


Published in:
European Journal of Pharmacology

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2016, The Authors
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including microglia, perivascular macrophages, and a small population of dendritic cells) and the complement system. Under normal aging conditions, retinal innate immune cells and the complement system undergo a low-grade activation (parainflammation) which is important for retinal homeostasis. In disease states such as AMD and DR, the parainflammatory response is dysregulated and develops into detrimental chronic inflammation. Complement activation in the retina is an important part of chronic inflammation and may contribute to retinal pathology in these disease states. Here, we review the evidence that supports the role of uncontrolled or dysregulated complement activation in various retinal degenerative and angiogenic conditions. We also discuss current strategies that are used to develop complement-based therapies for retinal diseases such as AMD. The potential benefits of complement inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to better understand the mechanisms of complement-mediated retinal damage in these disease states.
2. Tissue insults, inflammation and disease – the concept

The central role of the immune system is to protect the host from exogenous and endogenous insults. When a tissue suffers from non-infectious noxious insults, a cell-autonomous response is initiated for stressor elimination or stress adaptation. This may include the upregulation of the autophagy pathway, the initiation of DNA repair, and the induction of chaperones to help to prevent protein misfolding (the adaptation response). The adaptation response is especially important for aging and diabetes. In addition, a non-cell-autonomous response may also be initiated wherein stressed cells release cytokines, chemokines and growth factors that affect neighbouring cells within the tissue, promoting tissue level adaptation. In the literature, this tissue autonomous response (cell-autonomous or non-cell-autonomous) is often called “inflammation” when inflammatory cytokines and chemokines are released by stressed cells.

Although many cells can detect tissue stress, this function is performed most efficiently by specialized sensory cells, such as tissue resident macrophages. Thus, pathogens and generic stressors such as hypoxia and oxidized lipids/proteins are primarily delegated to macrophages. Tissue macrophages may orchestrate tissue level defence and adaptations by releasing inflammatory mediators, including complement components. If the level of insult exceeds the repair capacity of tissue macrophages, they may recruit circulating immune cells to sites of damage. A low-level of tissue insult may initiate a protective para-inflammation (Chovaliya and Medzhitov, 2014; Medzhitov, 2008). When the stress persists for a sustained period of time, the affected tissue may mal-adapt leading to loss of function. In addition, the immune system may respond inappropriately to tissue stress due to genetic and epigenetic modifications resulting in dysregulated para-inflammation (chronic inflammation). Tissue pathology (disease) may occur as a result of tissue mal-adaptation or immune dysregulation.

3. Retinal innate immune defence and disease

As an immune privileged tissue, circulating immune cells are not able to enter the retina to deal with endogenous insults under normal physiological conditions. However, the retina has a unique immune defence system consisting of innate immune cells and the complement system. The retina contains at least three types of innate immune cells: microglia, perivascular macrophages, and dendritic cells (DCs) (Forrester et al., 2010; Xu et al., 2009). Although both perivascular macrophages and microglia express...
CD11b and F4/80, the former expresses high levels of CD14 (LPS receptor) and CD45, whereas microglia are CD14^CD45\textsuperscript{low} (Dick et al., 1995; Fischer and Reichmann, 2001; Tavazzi et al., 2014). Perivascular macrophages safeguard retinal vessels and are critically involved in retinal vascular homeostasis. Whether or not the retina has DCs has been a debate for decades. Early work by Zhang and colleagues reported a small population of MHC-II\textsuperscript{+} cells in rat retina (Zhang et al., 1997). Using flow cytometry analysis, Gregerson and Yang detected a small population of CD11c\textsuperscript{+} DEC205\textsuperscript{+} DCs in normal mouse retina (Gregerson and Yang, 2003). They further confirmed the existence of retinal CD11c cells using CD11c-DTR transgenic mice (Lehmann et al., 2010), although a later study suggested that rd8 mutation in the Crb1 gene may contribute to the abnormal number of CD11c\textsuperscript{+} cells in the retina in CD11c-eYFP transgenic mice (Chen et al., 2013b). Previously, we identified a small population of MHC-II\textsuperscript{+}33D1\textsuperscript{+} DCs in mouse retina which are located around the optic disc and the peripheral retinal margin area (Xu et al., 2007). The function of these cells is unclear, but their strategic location suggests they may be “gatekeepers” of the retina. In experimental autoimmune uveoretinitis (EAU), these DCs are activated prior to overt retinal inflammation and their activation is associated with early cell infiltration around the optic disc and peripheral retinal margin (Xu et al., 2007). These retinal DCs are activated in experimental models of optic nerve degeneration and they can phagocytose dead ganglion cells (Heuss et al., 2014; Dick et al., 2014; Tavazzi et al., 2014). Ganglion cell degeneration/optic disc cupping is the key biological change in glaucoma. The MHC-II\textsuperscript{+}33D1\textsuperscript{+} juxtapapillary DCs may be critically involved in the pathogenesis of glaucoma. Microglia form an important part of retinal immune defence. They are located in the inner layers of the retina, and are distributed into three layers: the ganglion layer (GL), the inner plexiform layer (IPL) and outer plexiform layer (OPL) (Chen and Xu, 2015). Under normal physiological conditions, microglia are in a resting state with a small cell body and long, thin dendrites. They are activated in disease states, such as in AMD, DR, and uveoretinitis. Microglial activation may contribute to further retinal damage and disease progression. The role of retinal microglia in retinal health and disease has been reviewed extensively elsewhere (Karlstetter et al., 2010; Karlstetter et al., 2015; Langmann, 2007; Li et al., 2015).

In addition to retinal innate immune cells, compelling evidence suggests that the complement system also plays a critical role in protecting the retina from exogenous and endogenous insults. Dysregulated complement activation may contribute to retinal disease and targeting the complement system may offer opportunities for therapy.

4. The complement system

The complement system is an important part of the innate immune system. It complements antibodies and phagocytes to clear pathogens from the host. The complement system consists of over 30 small proteins and protein fragments and the majority of them are thought to be produced in the liver as inactive precursors and released into the circulation for tissue distribution. The complement system can be activated by at least three pathways: the classical pathway (CP), the mannose-binding lectin (MBL) pathway, and the alternative pathway (AP) (Fig. 2). There are two critical steps for the full activation of the complement pathways: C3 cleavage and C5 cleavage. A fully activated complement system results in the formation of the membrane attack complex (MAC, or C5b-C9) (Fig. 2) that can kill pathogens and cells. It is important to note that under physiological conditions, the complement system is constantly activated at a low-level (through the AP) and the harmful effects are prevented by various endogenous soluble and membrane-bound inhibitory molecules. For example, the MAC can be turned into harmless soluble SC5b-9 complex by S-protein/Vitronectin under physiological conditions (Su, 1996). In addition, recent evidence suggests that sub-lytic MAC may have immune modulatory roles, e.g., inducing IL-6, IL-8, CCL2 and VEGF production (Lakkaraju et al., 2014; Lueck et al., 2011). The key pathways and C3bBb of the AP. C5 is cleaved by C5 convertases, which include C4bC2b of the CP and MBL pathways and C3bBbC3b of the AP. Activation of the complement system generates C4a, C3a, C5b and C5a fragments that are actively involved in immune responses. C3b opsonizes foreign antigens and apoptotic cells, promoting phagocytosis. C3a and C5a are anaphylatoxins that have multiple immune regulatory roles. The C5b-C9 may directly kill pathogens or cells. The sub-lytic C5b-9 can also promote inflammation.

Fig. 2. Complement activation and immune regulation. The complement system can be activated by the classical pathway (CP), mannose-binding lectin (MBL) pathway and the alternative pathway (AP); all leads to the cleavage of C3 and C5 and the formation of C5b-C9. C3 is cleaved by C3 convertases, which include C4bC2b of the CP and MBL pathways and C3bBb of the AP. C5 is cleaved by C5 convertases, which include C4bC2bC3b of the CP and MBL pathways and C3bBbC3b of the AP. Activation of the complement system generates C4a, C3a, C5b and C5a fragments that are actively involved in immune responses. C3b opsonizes foreign antigens and apoptotic cells, promoting phagocytosis. C3a and C5a are anaphylatoxins that have multiple immune regulatory roles. The C5b-C9 may directly kill pathogens or cells. The sub-lytic C5b-9 can also promote inflammation.

Please cite this article as: Xu, H., Chen, M., Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.03.001
difference between different pathways rests on how the enzymes, i.e. C3 and C5 convertase, are formed. The convertases of C3 and C5 of the CP and the lectin pathway comprise the complement components C4bC2b and C4bC2bC3b respectively, while in the AP they are composed of C3bBb (C3 convertase) and C3bBbC3b (C5 convertase) (Fig. 2) (Zipfel and Skerka, 2009). In addition, complement can also be activated by a pathway that acts independently of C3 to bypass the C3 convertase and is mediated by direct thrombin action on the C5 convertase (Huber-Lang et al., 2006).

Traditionally the complement system is thought to be important for the elimination of invasive microbes (through cell lysis by MAC) and removal of waste (through opsonisation and promoting phagocytosis by C3b). Compelling evidence suggests that complement also plays critical roles in regulating inflammatory and immunological processes. Complement fragments C3a and C5a are anaphylatoxins and can induce vasodilation, increase the permeability of small blood vessels and induce contraction of smooth muscles (Fig. 2). C3a and C5a are chemotactic to neutrophils, mast cells, and lymphocytes. They can trigger oxidative burst in macrophages and eosinophils, and induce the release of histamine from basophils and mast cells (Fig. 2). C3a and C5a can enhance antigen presentation by DCs and promote Th1 cell differentiation (Sacks, 2010). In addition to their proinflammatory properties, C3a and C5a also participate in tissue regeneration and fibrosis (Hillebrandt et al., 2005; Strey et al., 2003).

C3a and C5a exert most of their biological activities through ligation of three cognate receptors: the C3a receptor (C3aR), the C5a receptor (C5aR), and the chemotactant receptor-like protein (C5L2). These receptors are widely expressed by immune cells and non-immune cells. Therefore, a fully activated complement pathway can modulate the immune response at multiple levels.

Recent evidence suggests that C3a can also be generated independent of complement activation through intracellular cleavage of C3 by cathepsin L (Liszewski et al., 2013). This local generation of anaphylatoxins is important for their pleiotropic biological effects beyond inflammation.

5. Complement regulation in the retina

Compelling evidence suggests that a complement regulatory system exists in the retina-RPE/choroid. The mRNA of complement components including C1qB, C1r, C2, C3, C4, complement factor B (CFB), and factor H (CFH) have been detected in the retina and RPE/choroid of human (Anderson et al., 2010) and mouse eyes (Luo et al., 2011). Retinal microglia and RPE cells appear to be the major cellular sources of local complement expression (Luo et al., 2011). The retina/RPE/choroid also expresses complement regulatory proteins. For example, CD46 was detected at the basal surface of RPE cells (Fett et al., 2012; Vogt et al., 2006), CD55 in ganglion and photoreceptors, CD59 in retinal nerve fibers (Vogt et al., 2006), and CFH in RPE (Chen et al., 2007) and choriocapillaris (Fett et al., 2012). The complement receptor CR1 and C3aR were detected in ganglion cells (Fett et al., 2012), whereas C5aR was detected in the inner plexiform layer (Vogt et al., 2006). In vitro studies have shown that RPE cells (Fukuoka and Medof, 2001), astrocytes (Gasque et al., 1995), and Muller cells (Cheng et al., 2013) all express C5aR.

An age-dependent upregulation of complement genes was observed in the retina (Chen et al., 2010a) and RPE/choroid (Chen et al., 2008a, 2008b) in mice. A recent study has reported an age-related accumulation of MAC in the choriocapillaris of healthy donor eyes (Chirco et al., 2015, Mullins et al., 2014). We have previously shown that expression of complement C3, C4, and CFB in mouse retina can be affected by cataract surgery (Xu et al., 2011) and irradiation (Chen et al., 2012). In vitro studies have further shown that complement expression by retinal cells is regulated by inflammatory cytokines and chemokines. For example, the expression of complement and regulatory genes by RPE cells can be regulated by cytokines such as TNF-α, IFN-γ, IL-27 (Amadi-Obi et al., 2012; Chen et al., 2007; Chen et al., 2008b; Lau et al., 2011) or the supernatants of macrophages (Luo et al., 2013). These results suggest that the retinal complement system is actively responding to ocular microenvironmental stimulations.

Although the physiological role of the complement system in retinal health and disease is not fully understood, the fact that the retina only express selected components of complement proteins and regulatory molecules suggests that the complement system cannot fully be activated if the BRB is intact. It also suggests that the retina has the capacity to control local complement activation when the BRB is broken down. This may have important implications in developing complement-based therapy for retinal diseases, i.e., controlling complement activation locally in the retina rather than systemically may be a more effective approach.

6. Complement activation and retinal diseases

6.1. Complement activation in Uveoretinitis

Uveoretinitis is an inflammatory condition that involves the uveal tract and the retina of the eye. The disease can cause devastating vision loss if left untreated. Current treatment of uveoretinitis is through local or systemic administration of immunosuppressants, which is often associated with severe adverse effects such as cataract and glaucoma and there is an urgent need to develop new effective and safe therapies.

Complement activation is known to be involved in the pathogenesis of uveoretinitis. The aqueous humor of uveitis patients contains high levels of C3a, C3c and CFB (Mondino et al., 1984). Polymorphisms in complement genes, including CFH, SERPING (Thompson et al., 2013; Yang et al., 2011; Yang et al., 2013), and C5 (Xu et al., 2015) increase the risk of uveitis. EAU is an established model of human posterior uveoretinitis (Caspi et al., 1990; Caspi et al., 1994; Forrester et al., 1992). The disease represents a T cell driven autoimmune response to retinal antigens (Caspi et al., 1990; Liversidge and Forrester, 1988) in which both Th1 and Th17 cells are involved (Amadi-Obi et al., 2007; Luger et al., 2008). Mice deficient in complement C3 are less susceptible to EAU (Read et al., 2006), whereas mice deficient in the decay-accelerating factor (DAF) develop greater EAU than their wild-type controls (An et al., 2009). Furthermore, EAU can be suppressed by introducing the soluble complement inhibitor (scry) (Read et al., 2006), recombinant DAF (An et al., 2009), or complement C5 monoclonal antibody (Copland et al., 2010). We have shown that CFB mRNA was significantly increased in EAU retina and that blocking the AP complement activation using fusion protein CR1g-Fc could suppress retinal inflammation in the mouse model of EAU (Chen et al., 2010b).

The complement system may contribute to retinal pathology in uveoretinitis at multiple levels. In addition to MAC-mediated cell death, C3a and C5a may modulate T cell activation. C5a/C5aR pathway is known to be involved in Th1 cell activation and deletion this pathway leads to Th17 and T regulatory (Treg) cell differentiation (Weaver et al., 2010; Xu et al., 2010). Mice deficient in C3aR/C5aR are resistant to EAU induction (Zhang et al., 2015).

6.2. Complement activation in AMD

AMD is the progressive degeneration of the macula (central part of the retina) in people aged over 55 years. AMD is the leading
cause of blindness in the elderly in developed countries, accounting for 8.7% of all blindness worldwide and is predicted to affect 196 million people by 2020 (Wong et al., 2014).

The early stages of the disease is characterised by large drusen (> 63 μm) and hypo- and hyper-pigmentation, so far the clinical predictive or therapeutic value of these markers is not known. The expression of complement inhibitors CD55 and C1r/C1s are suppressed in glaucoma retinae using proteomic analysis (2010) reported the upregulation of various complement components (predominately involved in CP) and down-regulation of complement inhibitors in glaucoma retinae using proteomic analysis. Using microarray techniques, Howell et al. (2011) showed that the complement cascade was upregulated at the early stages of the disease. On one hand, the generation of C3b is beneficial for retinal ganglion cell death in glaucoma. Tezel et al. (2010) reported the upregulation of various complement components (predominately involved in CP) and down-regulation of complement inhibitors in glaucoma retinae using proteomic analysis. Using microarray techniques, Howell et al. (2011) showed that the complement cascade was upregulated at the early stages of the disease. On one hand, the generation of C3b is beneficial for the control of IOP, glaucoma causes progressive peripheral vision loss and, if untreated, may lead to blindness. The most representative pathologic finding in glaucoma is the death of retinal ganglion cells by apoptosis.

Current treatment for glaucoma is aimed at reducing IOP using medicinal or surgical approaches. However a significant number of patients continue to lose vision after IOP is controlled. Compelling evidence suggests that inflammation, including complement activation contributes to ganglion cell death in glaucoma. Tezel et al. (2010) reported the upregulation of various complement components (predominately involved in CP) and down-regulation of complement inhibitors in glaucoma retinae using proteomic analysis. Using microarray techniques, Howell et al. (2011) showed that the complement cascade was upregulated at the early stages of the disease. In the experimental model of glaucoma, C5b-9 deposition was detected at the ganglion cell layer and complement depletion reduced ganglion cell loss (Jha et al., 2011). Furthermore, mice with C1qa or C5 (Howell et al., 2011; Howell et al., 2013) deficiency were protected from glaucoma. These results suggest that complement activation through the classical pathway may contribute to retinal ganglion cell death in glaucoma.

7. Targeting the complement system for the management of retinal disease

Despite convincing evidence that complement activation contributes to retinal pathology in the aforementioned sight-threatening diseases, so far the clinical predictive or therapeutic value of these findings has not materialized. When targeting the complement system for therapy, it is important to evaluate the beneficial and detrimental aspects of complement activation in retinal disease. On one hand, the generation of C3b is beneficial for
resolution of inflammation and tissue remodelling (through promoting phagocytosis of dead cells and debris). On the other hand, MAC-mediated cell death or C3a/C5a induced immune activation may contribute to retinal pathology. Ideally the therapy should be sufficient to constrain exacerbated complement activation without shutting down necessary biological functions pertinent to immune surveillance or tissue homeostasis. Complement activation involves a cascade of multiple steps, and each step might be targeted for therapy. The chosen therapy should consider the pathologic mechanisms of the disease such as the triggers of complement activation, the pathways, the location, and the disease course.

7.1. General principles for developing complement-targeted drugs

Avoiding toxicity: The complement system has many essential physiological roles in retinal defences. Therefore, any complement-targeted therapy should cause as little disruption of its physiological roles as possible, particularly if the treatment is to be continued in the long-term. The strategies to reduce the adverse effects related to complement inhibition may include: (1) targeting downstream of the complement pathway, i.e., MAC formation, for which the only risk is infection; (2) transient inhibition of complement activation (may only be applicable for acute diseases); (3) targeting complement activation locally in the retina. This should be the preferred approach to manage retinal diseases that are caused predominately by local variants, such as glaucoma and AMD. However, both glaucoma and AMD are chronic diseases, and may require long-term (years) management. The toxicity of long-term complement inhibition in the retina should be carefully considered. In DR and uveoretinitis the ocular barrier is often disrupted and systemic immune alteration contributes significantly to retinal pathogenesis. Although control of local immune activation, including complement activation is important for preserving retinal structure and function, rectifying the systemic immune response should also be considered, particularly at the acute stage of the disease.

Selecting targets for complement inhibition: How to control the complement system for the management of retinal diseases is an important and but often difficult question. With various potential sites of inhibition to be considered, the knowledge of how the complement system is activated and which pathways are involved will be essential to identify the target of inhibition. In general, the targets that can be considered for therapy may include the initiators, regulators, and amplification of the cascade, and the effectors of the complement system. The initiators include complement components that form the activation complex (e.g., C1q in the CP, C3 in the AP, and MBL in the lectin pathway) and relevant enzymes (C1r and C1s in the CP, MASPs1 and MASPs2 in the lectin pathway, and C3 convertases in the AP). The regulators include membrane-bound molecules (SIGNR, CR1-4, CRlg, CD46, CD55, CD59) and soluble proteins (C4BP, C1INH, CFH, CFHR1, FH1, properdin, clusterin, vitronectin) that negatively regulate complement activation (Zipfel and Skerka, 2009) as well as enzymes involved in the amplification stage (e.g., factor D). The effectors include C5b-9 (MAC) and the anaphylactic proteins C3a and C5a. The targeting approaches may include neutralizing antibodies against the assembling compounds, enzymes or the synthetics of the inhibitors. There are a number of complement inhibitors that selectively target each of the above points that have been approved by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) in clinical development and others are in pre-clinical development for inflammatory diseases such as hemolytic uremic syndrome, ischemia-reperfusion injury, organ transplant rejection, and thrombotic microangiopathy (Reis et al., 2015) (Table 1).

In different retinal diseases the complement system contributes differently to the pathogenesis. Therefore, treatment strategies should differ depending on disease pathogenesis. In uveoretinitis, for example, the effectors (MAC, C5a) are known to play a key role in retinal damage, and a previous study has shown that targeting C5 (local or systemic) could effectively suppress experimental autoimmune uveoretinitis (Copland et al., 2010). Regrettably, little is known about how the complement system damages the retina in other disease conditions including AMD despite many years of intensive study. That is reflected by the poor outcomes in complement based clinical trials (see below).

7.2. Current progress in complement based therapy for retinal diseases

There are a number of complement-targeting drugs in clinical (Table 2) and pre-clinical trials for retinal diseases, predominately for the management of AMD with only one trial for non-infections uveitis patients (NCT01526889, Table 2), and two trials for optic neuritis (NCT02003144, NCT01759602, Table 2).

7.2.1. Non-infectious Uveitis

LFG316 is a C5-specific mAb developed by Novartis. It is in phase 2 clinical trials for a number of complement related diseases, including Paroxysmal nocturnal hemoglobinuria (PNH), AMD, and non-infectious uveitis. In the uveitis study (NCT01526889), LFG316 will be administered intravitreally (IVT) to patients with active, non-infectious intermediate-, posterior-, or panuveitis, and the safety, efficacy and pharmacokinetics will be assessed over a 12-week period. The trial is ongoing.

7.2.2. AMD

There are a number complement inhibitors are in phase 1-3 clinical trials for the treatment of AMD (Table 2), including one inhibitor (POE-4) targeting C3, four (LFG316, Eculizumab, Zimura, and ARC1905) targeting C5, and another one targeting factor D (Lampalizumab formerly FCDF4514S). The majority of the trials have shown a good record of safety, however the efficacy remains to be determined.

C3-targeted inhibitor: POT-4/Compostatin is a cyclic peptide that inhibits C3 cleavage and prevents complement activation. An in vitro study has shown that compostatin could inhibit drusen-like deposits in human RPE cultures (Gorham et al., 2013). Furthermore, an in vivo study in a monkey model of early-onset macular degeneration observed the disappearance of drusen 6 months after intravitreal injection of compostatin (Chi et al., 2010). A phase 1 study to evaluate the safety and tolerability of intravitreal POT-4 injection for treatment of patients with neovascular AMD was conducted between 2007 and 2010 (NCT00473928). However, positive results, if any, have never been reported.

C5-targeted inhibitors: LFG316 is a fully-human, high-affinity antibody against C5 and can prevent C5 cleavage. The phase 2 studies of LFG316 for both GA (NCT01527500) and neovascular AMD (NCT01535950) were completed in 2015, and the results are yet to be reported.

Eculizumab, another C5 specific mAb, had been approved for the treatment of PNH and atypical hemolytic uremic syndrome (aHUS) (Rother et al., 2007). A phase 2 study has shown that up to 24 weeks intravenous infusions of Eculizumab was well-tolerated by AMD patients through 52 weeks follow-up (Yehoshua et al., 2014). However, neither GA progression (Yehoshua et al., 2014) nor drusen volume (Garcia Filho et al., 2014) was affected by the treatment despite significant reduction on circulating C5 activity (to less than 9% of normal levels by week one and less than 1% by week two after treatment) (Yehoshua et al., 2014). The results suggest that systemic complement activation may have limited
Table 1
Complement inhibitors that have been approved or are in preclinical or clinical studies.

<table>
<thead>
<tr>
<th>Target point</th>
<th>Compounds</th>
<th>Mechanism of inhibition</th>
<th>Company</th>
<th>Application and Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Berinert</td>
<td>Plasma-derived human C1-INH</td>
<td>CSL Behring</td>
<td>Approved for hereditary angioedema (HAE)</td>
</tr>
<tr>
<td></td>
<td>Ruconest</td>
<td>C1 esterase inhibitor (recombinant)</td>
<td>Pharming Group N.V.</td>
<td>Approved for HAE</td>
</tr>
<tr>
<td></td>
<td>Cinryze</td>
<td>Plasma-derived human C1-INH</td>
<td>VirotPharma Biologics</td>
<td>Approved for HAE</td>
</tr>
<tr>
<td></td>
<td>TNT009</td>
<td>C1 inhibitor (mAb)</td>
<td>True North Therapeutics</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>OMS721</td>
<td>MASP-2 antibody</td>
<td>Omeros Corporation</td>
<td>Thrombotic microangiopathies, phase 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genentech</td>
<td>Approved for Paroxysmal nocturnal hemoglobinuria (PNH) and aHUS; phase 3 trials for AMD</td>
</tr>
<tr>
<td><strong>Regulators or amplification cascades</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>APL-1/2</td>
<td>C3 (Comstatin derivatives)</td>
<td>Apellis Pharmaceuticals</td>
<td>Phase 1 for PNH</td>
</tr>
<tr>
<td></td>
<td>AMY-101</td>
<td>C3 (Comstatin derivatives)</td>
<td>Amynadas Pharmaceuticals</td>
<td>Pre-clinical study in PNH</td>
</tr>
<tr>
<td></td>
<td>TP10</td>
<td>Soluble CR1</td>
<td>Celldex</td>
<td>Phase 1 for patients with C3 glomerulopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase 2 for adult women undergoing cardiopulmonary bypass surgery</td>
</tr>
<tr>
<td></td>
<td>TT30</td>
<td>Fusion protein linking CR2 and CFH</td>
<td>Alexion Pharmaceuticals</td>
<td>Phase 2 or PNH</td>
</tr>
<tr>
<td></td>
<td>Mini-FH</td>
<td>Engineered version of CFH</td>
<td>Adienne S.A.</td>
<td>Pre-clinical study in C3 glomerulopathy</td>
</tr>
<tr>
<td></td>
<td>Mubodina/Ergidina</td>
<td>C5 specific mAb</td>
<td>Amynadas Pharmaceuticals</td>
<td>Pre-clinical study in aHUS</td>
</tr>
<tr>
<td></td>
<td>Eculizumab</td>
<td>C5 specific mAb</td>
<td>Alexion Pharmaceuticals</td>
<td>Approved for PNH and aHUS; Phase 1–2trials for neuromyelitis optica, kidney graft reperfusion injury, AMD, myasthenia gravis, Guillaume-Barre syndrome, etc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both are synthesized C5 inhibitors (aptamer)</td>
<td>Ophthotech</td>
<td>Phase 2 for AMD</td>
</tr>
<tr>
<td></td>
<td>LFG316</td>
<td>C5 specific mAb</td>
<td>Novartis</td>
<td>Phase 2 for AMD, PNH and non-infectious uveitis</td>
</tr>
<tr>
<td></td>
<td>Coversin</td>
<td>Recombinant small protein (prevents C5 cleavage)</td>
<td>AKARI Therapeutics</td>
<td>Phase 2 for PNH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Effectors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zimura, ARChO5</td>
<td>Both are synthesized C5 inhibitors (aptamer)</td>
<td>Ophthotech</td>
<td>Phase 2 for AMD</td>
</tr>
<tr>
<td></td>
<td>LFG316</td>
<td>C5 specific mAb</td>
<td>Novartis</td>
<td>Phase 2 for AMD, PNH and non-infectious uveitis</td>
</tr>
<tr>
<td></td>
<td>Coversin</td>
<td>Recombinant small protein (prevents C5 cleavage)</td>
<td>AKARI Therapeutics</td>
<td>Phase 2 for PNH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALN–CC5</td>
<td>C3 specific RNAi</td>
<td>Alnylam</td>
<td>Phase 1 and 2 for PNH</td>
</tr>
<tr>
<td></td>
<td>CaCP29</td>
<td>C5a specific mAb</td>
<td>InflaRx</td>
<td>Phase 2 for septic organ dysfunction</td>
</tr>
<tr>
<td></td>
<td>CCX168</td>
<td>C5aR inhibitor</td>
<td>ChemoCentryx</td>
<td>Phase 2 for aHUS, ANCA-associated vasculitis, and IgA nephropathy</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Compound</th>
<th>Target</th>
<th>Structure</th>
<th>Source</th>
<th>Trial status</th>
<th>Indications</th>
<th>Trial number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zimura®</td>
<td>CFD</td>
<td>C5</td>
<td>AptaMer</td>
<td>Phase 1</td>
<td>Combined therapy with anti-VEGF</td>
<td>NCT00709527</td>
</tr>
<tr>
<td>ARC1905</td>
<td>CFD</td>
<td>C5</td>
<td>AptaMer</td>
<td>Phase 2</td>
<td>Advanced neovascular AMD</td>
<td>NCT02397954</td>
</tr>
<tr>
<td>Lampalizumab (FCFD4514S)</td>
<td>CFD</td>
<td>C5</td>
<td>Monoclonal antibody (Fab fragment)</td>
<td>Phase 2 completed (Rhoads et al., 2015)</td>
<td>Neovascular AMD</td>
<td>NCT00795638</td>
</tr>
<tr>
<td>CINRYZE (C1-INH)</td>
<td>C1-INH</td>
<td>C1 esterase inhibitor</td>
<td>La Roche</td>
<td>Phase 1, completed (Levy and Mealy, 2014)</td>
<td>Neuromyelitis optica (NMO), optic neuritis</td>
<td>NCT01759602</td>
</tr>
<tr>
<td>eculizumab</td>
<td>C5</td>
<td>Monoclonal antibody</td>
<td>Alexion Pharmaceuticals</td>
<td>Phase 1</td>
<td>Advanced neovascular AMD</td>
<td>NCT00935883</td>
</tr>
</tbody>
</table>
| Factor D (CFD-targeted inhibitor): Factor D (CFD) is responsible for AP-mediated complement activation. Lampalizumab (FCFD4514S) is a humanized IgG Fab fragment directed against CFD. Intravitreal injection of lampalizumab in cynomolgus monkeys at high doses resulted in transient inhibition of systemic AP activity (Loyet et al., 2014). The results from phase 1–2 studies were published on June 11, 2015 in Clinical Ophthalmology (Rhoades et al., 2015). Interestingly, the paper was retracted two weeks later (June 26, 2015) because “the results referenced in this manuscript are preliminary analyses and may not reflect the final data and conclusions of the clinical trials cited”. Nevertheless, the paper reported that (1) a phase 1 study showed that intravitreal injection of lampalizumab (up to 10 mg) was well-tolerated through 90 days by GA patients; (2) a phase 2 study (MAHALO) showed that the size of GA reduced by 20.4% from baseline after 18 months treatment. Further subgroup analysis revealed a 44% reduction in patients who were positive for exploratory biomarkers (i.e., mutations for CFH, C3, or C2/CFB) (P < 0.005) (Rhoades et al., 2015). Phase 3 clinical trials to evaluate the efficacy and safety of intravitreal injection of lampalizumab for the treatment of GA are ongoing (Table 2) (PharmaTimes).

Despite millions of dollars having been spent and nearly a decade of intense research, the results so far from the clinical trials have produced disappointing primary outcomes (i.e., minimal improvement in visual acuity or reduction in disease progression) (Table 2). Most of these trials have ended early as a result of disappointing interim results and others with no reason reported (with only one exception, Table 2). The disappointing results from clinical trials have highlighted our lack of basic understanding about the mechanisms by which complement factors influence AMD development (Reynolds et al., 2009, Scholl et al., 2008). Thus we are unable to address precisely when, where, and how to inhibit complement activation in different types of AMD.

Since AMD has strong genetic predisposition, it has been proposed that genetic screening may help to predict treatment responsiveness. Indeed the MAHALO study, although preliminary, has observed better responses to Lampalizumab from GA patients with complement gene mutations (Rhoades et al., 2015). However, the data about whether polymorphisms in complement genes and other AMD risk factor genes can be used to predict the response to VEGFA-targeted therapies are conflicting (Hagstrom et al., 2013, Smallhodzic et al., 2012). Similarly, genetic models fail to predict progression to geographic atrophy (Klein et al., 2010, Scholl et al., 2009). We have shown recently that the level of complement activation differs in different types of AMD (Lechner et al., 2016). A complex approach, taking into account genetic information, environmental risk factors, biological phenotypes and clinical presentation, may be a more appropriate way forward in developing complement based personalized therapy for AMD and other retinal diseases.

8. Future perspectives and conclusions

The discovery of the link between complement gene polymorphisms and AMD risk has prompted a resurgence in investigating the role of the complement system in retinal diseases.

---

**Note:** The table and text above provide a comprehensive overview of the clinical trials targeting the complement system for the management of retinal degenerative diseases, highlighting the status, indication, and outcomes of each trial. The text also discusses the disappointing results from clinical trials and the need for a more integrated approach to complement-based personalized therapy for AMD and other retinal diseases.
As a result, our knowledge of this topic has advanced considerably in the past decade, which has prompted the design of distinct strategies to develop complement based therapies for AMD patients. There are a few FDA approved complement inhibitors for other inflammatory diseases, and clinical experience from these studies suggests that complement-targeted therapies can be safe and effective. In addition, there are over 40 ongoing clinical trials evaluating different classes of complement inhibitors in numerous diseases. These clinical studies will provide valuable information about the safety and efficacy of distinct strategies for complement targeting, which offers a great opportunity to develop complement-based therapies for sight-threatening retinal diseases. For each retinal disease, future research should address how the complement system is activated, which complement pathway is involved, which complement components cause retinal pathology and at which stage of the disease, and whether the complement system affects the eye systemically or locally. This knowledge will be important in deciding whether complement inhibition should be applied systemically or locally to treat disease, and when and how the complement system should be targeted for therapy. As complement activation is not the initial cause of the disease, it is understandable that complement inhibition on its own may not be sufficient to control retinal pathology, and concomitant targeting of disease aetiology may maximize the benefits.

Disclosures

The authors declare no competing financial interests.

Acknowledgements

Funding support is provided by Fight for Sight (1361/1362; 1425/1426), Diabetes UK (11/0004230; 13/0004729), Dunhill Medical Trust (R188/0211), and National Eye Research Center (SCIAD 061). The authors acknowledge the researchers who have greatly contributed to this field, but whose work was not cited as a result of space limitations. The authors thank Daniel C. Xu (Oxford University) for critically reading the manuscript and for helping with English expression.

References

225–240.
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Oph-
Rhoades, W., Dickson, D., Do, D.V., 2015. Potential role of Lampalizumab for treat-
Romero-Aroca, P., Sagarra-Altamiro, A., Basora-Gallisa, J., Basora-Gallisa, T., Baget-
Bernaldez, M., Bautista-Perez, A., 2010. Prospective comparison of two methods of
screening for diabetic retinopathy by Nonmydriatic fundus camera. Clin. Ophthal-
mol. 4, 1481–1488.
development of the complement inhibitor Eculizumab for the treatment of
Sacks, S.H., 2010. Complement fragments C3a and C5a: the salt and pepper of
Scholl, H.P., Charbel Issa, P., Waller, M., Janzer, S., Pollok-Kopp, B., Borncke, F.,
Fritsche, L.G., Chong, N.V., Fimmers, R., Wienker, T., Holz, F.G., Weber, B.H.,
Oppermann, M., 2008. Systemic complement activation in age-related macular
degeneration. PLOS One 3, e2593.
Scholl, H.P., Fleckenstein, M., Fritsche, L.G., Schmitz-Valkenberg, S., Gobel, A.,
Adrian, C., Herold, C., Keilhauer, C.N., Mackensen, F., Moxness, A., Pauleikhoff,
C3 and ARMS2 are significant risk loci for susceptibility but not for disease
progression of geographic atrophy due to AMD. PLOS One 4, e7418.
Simo, R., Hernandez, C., European Consortium for the Early Treatment of Diabetic
Retinopathy (EUROCONDOR), 2012. Neurodegeneration is an early event in
Smialdzeic, D., Muether, P.S., Chen, J., Kwestro, A., Zhang, A.Y., Omar, A., Van de
Ven, J.F., Keunen, J.E., Kirchhof, B., Hoyng, C.B., Klevering, B.J., Koenekoop, R.K.,
Fauser, S., den Hollander, A.I., 2012. Cumulative effect of risk alleles in CH,
ARMS2, and VEGFA on the risk to develop age-related macular degeneration. Ophthalmology 119, 2304–2311.
Res. 18, 397–370.
Steinlein, J.W., Ma, N., Wenkel, H., Ng, T.F., Zamiri, P., 2002. Immunobiology and
privilege of neuronal retina and pigment epithelium transplants. Vis. Res. 42,
358–369.
Streilein, J.W., Yang, M.M., Lai, T.Y., Tam, P.O., Chiang, S.W., Chan, C.K., Luk, F.O., Ng, T.K., Pang, C.P.,
Retin. Eye Res. 28, 348–368.
Xu, H., Chen, M., Forrester, J.V., 2011. Cataract surgery induces retinal pro-
Sci. 52, 249–255.
Sci. 48, 1701–1716.
Xu, R., Wang, R., Han, G., Wang, J., Chen, G., Wang, L., Xu, G., Ruo, S., Shen, B., Li, Y.,
2010. Complement C5a regulates IL-17 by affecting the crosstalk between DC
Yang, M.M., Lai, T.Y., Tam, P.O., Chiang, S.W., Chan, C.K., Luk, F.O., Ng, T.K., Pang, C.P.,
2011. CH1 184G as a genetic risk marker for anterior Uveitis. Invest. Ophthal-
Retin. Eye Res. 28, 348–368.
Xu, H., Chen, M., Forrester, J.V., 2011. Cataract surgery induces retinal pro-
Sci. 52, 249–255.
1848–1849.
Yehoshua, Z., Filho, de Amorim Garcia, Nunes, C.A., Gregori, P., Penha, G., Mosh-
complement inhibition with Eculizumab for geographic atrophy in age-related
Sci. 46, 908–919.
Zhang, J., Gerhardinger, C., Lorenzi, M., 2002. Early complement activation and
decreased levels of glycosylphosphatidylinositol-anchored complement inhib-
Zhang, L., Bell, B.A., Yu, M., Chan, C.C., Peacdy, N.S., Fung, J., Zhang, X., Caspi, R.R.,
Lin, F., 2015. Complement anaphylatoxin receptors C3aR and C5aR are required in
the pathogenesis of experimental autoimmune uveitis. J. Leukoc. Biol.

Please cite this article as: Xu, H., Chen, M., Targeting the complement system for the management of retinal inflammatory and
degenerative diseases. Eur J Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.03.001